TRDA

Based on Entrada Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Entrada Therapeutics do?

Entrada Therapeutics is a biotechnology company developing therapies for neuromuscular diseases using its proprietary endosomal escape vehicle (EEV) platform. This technology is designed to deliver oligonucleotide, antibody, and enzyme-based treatments directly into cells. Its lead programs target Duchenne muscular dystrophy and myotonic dystrophy type 1.

Does TRDA pay dividends?

No, Entrada Therapeutics does not pay a dividend. As a preclinical-stage biotech, the company reinvests all capital into research and development. Investors should not expect income distributions from TRDA in the near term.

When does TRDA report earnings?

Entrada Therapeutics follows a standard quarterly reporting cadence for US-listed companies. Because it is a preclinical-stage company, reports focus on operating expenses and cash position rather than revenue. Check Entrada's investor relations page for the most current schedule.

Is TRDA a good stock to buy?

UQS Score rates TRDA as Poor overall, driven by Weak Quality, Moat, and Growth pillars alongside an Elevated Valuation. This profile reflects the high uncertainty of early-stage drug development. Whether it fits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro.

Is TRDA overvalued?

The UQS Valuation pillar for TRDA is rated Elevated, suggesting the current market price may not fully account for the execution and clinical risks the company faces. For a pre-revenue biotech, valuation is often driven by pipeline optionality rather than fundamentals, which can create meaningful downside if milestones are missed.

How does TRDA compare to its competitors?

Entrada competes in the small-cap rare disease and specialty biotech space alongside companies like ADC Therapeutics, 4D Molecular Therapeutics, and Relmada Therapeutics. Each pursues different therapeutic modalities and disease areas. Entrada's differentiation lies in its EEV delivery platform, which is distinct from gene therapy or small-molecule approaches used by peers.

What is TRDA's market cap bracket?

Entrada Therapeutics is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, which is common for clinical and preclinical-stage biotechnology firms.

Who founded Entrada Therapeutics?

Entrada Therapeutics was originally incorporated as CycloPorters, Inc. in 2016 before rebranding to its current name in October 2017. Founding details and leadership history are publicly available through the company's filings and investor relations materials.

Is TRDA a long-term quality investment?

As a long-term quality indicator, TRDA's current UQS profile — with Weak Quality, Moat, and Growth pillars — suggests the company has not yet demonstrated the durable characteristics associated with high-quality long-term holdings. Pipeline success could change this picture, but significant uncertainty remains at this stage of development.

What is the main competitive advantage of Entrada Therapeutics?

Entrada's primary differentiator is its endosomal escape vehicle platform, which aims to solve a fundamental challenge in drug delivery — getting therapeutic molecules inside cells efficiently. If validated clinically, this platform could support multiple programs across neuromuscular diseases. However, the Moat pillar is currently rated Weak, reflecting that this advantage is not yet commercially proven.

What sector does TRDA belong to?

Entrada Therapeutics operates in the Healthcare sector, specifically within biotechnology. It focuses on rare and neuromuscular diseases, a subsegment that attracts both scientific interest and regulatory incentives such as orphan drug designation, though it also carries significant clinical development risk.

Is TRDA a growth stock or value stock?

Based on its UQS profile, TRDA does not fit neatly into either category. Its Growth pillar is rated Weak — reflecting the absence of revenue and uncertain pipeline timelines — while its Valuation pillar is Elevated, meaning it does not screen as a traditional value opportunity either. It is best characterized as a high-risk, pipeline-dependent biotech.

Entrada Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Entrada Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.

Entrada Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.

Entrada Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Entrada Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TRDA.

The UQS (Unified Quality Score) for Entrada Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Entrada Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Entrada Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.